Hong Kong Baptist University

HKBU and Shanghai Sixth People's Hospital discovered an aptamer, Apc001, effective for X-linked hypophosphatemia (XLH). Granted Orphan Drug and Pediatric Rare Disease Designations by the FDA, Apc001 is set for clinical trials in Mainland China and the US.

HKBU's aptamer for treating X-linked hypophosphatemia (XLH) received Orphan Drug and Rare Pediatric Disease Designations from the U.S. FDA. The aptamer, Apc001, targets sclerostin's loop3 domain to promote bone formation without cardiovascular risks, and is set for clinical trials in China and the U.S.